Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. - Wikidata - awgldk - TriplyDB

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

http://www.wikidata.org/entity/Q33392694

about

Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Outpatient therapeutic nuclear oncology.Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.A multimodal approach to the management of neuroendocrine tumour liver metastases A new era for the systemic therapy of neuroendocrine tumors.Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.Evaluation of two intraoperative gamma detectors for assessment of 177Lu activity concentration in vivo.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs Therapeutic strategies for neuroendocrine liver metastases.Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors.[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Radionuclide Therapy for Neuroendocrine Tumors.Effects of low-dose capecitabine on Samarium-153-EDTMP therapy for painful bone metastases Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?Management of fear of radiation exposure in carers of outpatients treated with iodine-131.Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.Radionuclides in oncology clinical practice - review of the literature.Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.Targeted Therapy for Medullary Thyroid Cancer: A Review.Theranostics of Neuroendocrine Tumors.Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.[Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine].

P2860

Q28071978-2715ECA3-5B4A-40C4-BB62-5647CE672E6F Q28247667-B529B90B-C841-4D48-9CAA-5687A0A98C6B Q30364864-3641D769-D1DC-4B70-857A-E04EB7860FCF Q33961370-BC9B3823-AF4B-4022-BB1D-6B38AE0E6AD1 Q34157391-21686582-388F-4B96-8DCB-81B23ED04A42 Q34244990-0B69E077-272C-436E-A53E-76166F5C52A6 Q34318792-53BA1CB8-9CD8-4889-A385-018AD04F762D Q34414279-38E14B44-B77D-48AA-ACFA-7E2E4F78247F Q35738251-9062BE89-0939-4141-9560-1F6237848617 Q35810562-50BFEA72-E513-416B-BDEA-E90E30013DE7 Q35863865-3E591839-E7D5-4607-A312-662A26AED2CD Q35999552-E8EEE53D-B8EA-4F1E-837C-9471540B8BDA Q37143853-CBD19B38-81B9-4947-97E3-8700A9DC577C Q37167160-750188A7-DC66-410E-A7E2-B1879ED338DA Q37574732-3B009208-5867-4432-9174-326EEB0CF773 Q37975101-B6942602-56A1-45BD-B633-909DD43BDFBD Q38241463-17FDB104-4CB2-4FBD-AFBB-2E2198A27843 Q38255979-98CCD6C5-65FA-4A49-B487-98811BBF7A53 Q38262113-DF6C12A3-11DD-4B90-8F9E-23A46F8CDEE3 Q38271733-6B949105-EDE0-46D1-9297-4A9CA46CA147 Q38581192-5B71A6B7-5D7E-4726-93B6-B3B922539DC1 Q38694105-400A929F-3F06-4380-9529-E38B40D6A061 Q38909078-8C876A48-2292-4030-B407-F9E44D696487 Q39144880-C72CEBA1-E52C-46DE-B51E-C6D00965B581 Q39191700-3C0B87F0-602C-4CC2-9FB8-D55A7ACD7490 Q42345704-62C07E07-B46B-4D88-801D-AB7C595E094E Q44670305-01E5E45D-4CF1-4FF7-921F-9CD38B82822F Q46645822-0097E221-5851-4FC6-A2AB-202E540B25F7 Q47128709-09E71DAD-260B-47DF-98EC-57640ED61512 Q47916271-A9A6DA35-50C3-4CA4-98D9-414D55FEE05C Q47988504-94609CD3-6D41-4B3B-98B3-8106D4574F7C Q48148957-71D78869-6E82-456D-8DCB-DFAB463EF7AC Q49328959-1E2C0408-484F-4DDF-B02E-037B69DBFFE0 Q49612068-D4962EB1-43C0-4A45-8435-FD9FF48D49C7 Q50034009-801F75A9-2340-4D52-81A2-D1567B7270F8 Q50143284-AF24DA77-5274-4574-84BC-F70E6E2E1C21 Q52964782-B865B704-7DA8-4534-917F-D5649184C57A Q52987702-C304FF0A-9474-4A6B-93EB-0DB1657994AC Q53092330-22F822F2-2068-40D0-A897-BA6B10E8FEB5 Q53181259-9BA5CA6D-7C11-4096-8186-1581ED0E16E7

P2860

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

http://www.wikidata.org/entity/Q33392694

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II study of radiopeptide ...... inated neuroendocrine tumours.

@ast

Phase II study of radiopeptide ...... inated neuroendocrine tumours.

@en

type

label

Phase II study of radiopeptide ...... inated neuroendocrine tumours.

@ast

Phase II study of radiopeptide ...... inated neuroendocrine tumours.

@en

prefLabel

Phase II study of radiopeptide ...... inated neuroendocrine tumours.

@ast

Phase II study of radiopeptide ...... inated neuroendocrine tumours.

@en

P1433

Q33392694-94E7507D-96BF-4F2E-ABE6-48E8121B4F64

P1476

Q33392694-22489D43-A83C-43DF-A67C-3A5DF8971879

P2093

Q33392694-77DF6F0B-5AD1-463B-8001-481D8FAB6E25

Q33392694-A7C0D63D-A84A-4C75-A1FA-72EEA17124C9

Q33392694-D3358852-969B-4B2C-8474-B844A587CC17

Q33392694-D5C37A40-60DD-431D-83FB-0233E503BD11

P2860

Q33392694-1EA32B89-838B-457E-B119-6E826DADCCC8

Q33392694-1FAD4CDA-575D-40FE-8E86-B19345158E87

Q33392694-22505CE2-F86F-4D3C-9534-529FB8EE80CE

Q33392694-25AF99A8-AA5B-4BA1-8417-E881FC51AC77

Q33392694-3293336D-DB8D-4C83-BC8A-9D4D49103E9A

Q33392694-37C2C0F9-5749-4A81-9485-FD51A91D5F99

Q33392694-3A2E4CCE-F31D-4DDD-BE5B-C1C4AD0205AC

Q33392694-4482281E-6178-442C-BBEB-C2747CC086C3

Q33392694-45D80671-80AF-488F-940B-4673CE16A6CB

Q33392694-55955516-A83E-4EA6-A624-8E7FB0F17CE2

P2888

Q33392694-AB9E5DDB-19FF-43DD-B5AC-0CD9F8505660

P304

Q33392694-7FD5288C-FF73-4B0F-AF71-3F5C92A59F95

P31

Q33392694-2A1E0CAA-8A95-43A7-B2CC-64E98CACE89D

P356

Q33392694-B70D27D7-68C8-4233-A93E-F6D7B3B9C87F

P433

Q33392694-68526858-E190-4C51-893F-C074B890D57C

P478

Q33392694-EFA949C1-0A41-4CE1-A746-3C37AD18F13E

P577

Q33392694-492C3CCB-A1D2-4D67-AFC5-6C8E362DC965

P698

Q33392694-DAF4F9A8-DB6A-437D-81F5-86FB60F7CEC4

P356

S00259-010-1631-X

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Phase II study of radiopeptide ...... inated neuroendocrine tumours.

@en

P2093

J Harvey Turner

http://www.w3.org/2001/XMLSchema#string

Paul A Brayshaw

http://www.w3.org/2001/XMLSchema#string

Phillip G Claringbold

http://www.w3.org/2001/XMLSchema#string

Richard A Price

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Two-sided confidence intervals for the single proportion: comparison of seven methods

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

Therapeutic options for gastrointestinal carcinoids.

Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.

Neuroendocrine tumors of the diffuse neuroendocrine system.

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.

P2888

s00259-010-1631-x

P304

302-311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-010-1631-X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21052661

http://www.w3.org/2001/XMLSchema#string